文献速递神经肿瘤

无边缘分次射波刀立体定向放疗用于视路旁垂体腺瘤

Fractionated CyberKnife Stereotactic Radiotherapy for Perioptic Pituitary Adenomas.
PubMed 文献 · World Neurosurg · 2019-03-19

研究纳入53例距视路装置3 mm以内的垂体腺瘤患者,采用无边缘分次(25-28次)射波刀立体定向放疗。平均随访32.5个月时肿瘤控制率为98.1%(52/53),全部患者视力保持或改善,52/53例(98.1%)垂体功能无变化,激素分泌型肿瘤内分泌控制率为75%(6/8)。作者认为该方案局部肿瘤控制与内分泌控制率良好,与立体定向放射外科(SRS)相当,并保持了视力。

要点

  • 距视路3 mm以内的垂体腺瘤采用无边缘分次射波刀放疗,肿瘤控制率为98.1%(52/53)。
  • 全部患者原有视力保持或改善,52/53例(98.1%)垂体功能无变化。
  • 激素分泌型肿瘤内分泌控制率为75%(6/8)。

核心结论

  • 无边缘分次射波刀放疗在距视路很近的垂体腺瘤中显示出良好的局部肿瘤控制率和内分泌控制率,与SRS相当,并保持了视力。

研究设计与样本

  • 单臂临床结局研究,共53例距视路装置3 mm以内的垂体腺瘤患者接受无边缘分次(25-28次)射波刀立体定向放疗;主要终点为肿瘤控制,次要终点为视力与垂体功能保存及激素分泌型肿瘤的内分泌控制。

主要发现

  • 平均随访32.5个月(范围3-77个月)时,MRI评价肿瘤稳定或缩小的肿瘤控制率为98.1%(52/53)。
  • 全部患者原有视力状态保持或改善。
  • 52/53例(98.1%)垂体功能无变化;1例在治疗后4个月因垂体卒中出现垂体功能恶化。
  • 激素分泌型肿瘤的内分泌控制率为75%(6/8)。

关键数值与推荐

  • 分次方案为25-28次。
  • 肿瘤控制率98.1%(52/53),平均随访32.5个月(范围3-77个月)。
  • 垂体功能无变化者52/53例(98.1%)。
  • 激素分泌型肿瘤内分泌控制率75%(6/8)。

临床怎么用

  • 作者认为,对于距视路很近、不适合SRS的垂体腺瘤,无边缘分次射波刀放疗可获得与SRS相当的局部肿瘤控制和内分泌控制率,并保持视力。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Stereotactic radiosurgery (SRS) is the reference standard for radiotherapy for pituitary adenomas but has been limited to lesions with sufficient distance (i.e., >3 mm) from the optic apparatus. We used marginless, fractionated (i.e., 25-28 fractions) stereotactic radiotherapy and the CyberKnife to treat pituitary adenomas that were not eligible for SRS. We present the clinical outcomes, including local control, endocrine function, and toxicity from modern fractionated radiotherapy. METHODS: A total of 53 patients were treated for pituitary adenomas within 3 mm of the optic apparatus. The primary endpoint was tumor control with the secondary endpoints of vision and pituitary function preservation and endocrine control in hormone-secreting tumors. RESULTS: The tumor control rate as measured on magnetic resonance imaging as either stable or decreased in size was 98.1% (52 of 53) at a mean follow-up of 32.5 months (range, 3-77). All patients experienced preservation or improvement of their preexisting vision status. No change in pituitary function was noted in 52 of the 53 patients (98.1%). One patient experienced worsening of pituitary function secondary to pituitary apoplexy that occurred 4 months after treatment. The endocrine control rate in hormone-secreting tumors was 75% (6 of 8). CONCLUSIONS: Marginless, fractionated CyberKnife radiotherapy demonstrated excellent local tumor control and endocrine control rates, comparable to those with SRS, with preservation of vision in patients with adenomas in close proximity to the optic pathway.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Plitt AR, El Ahmadieh TY, Aoun SG, et al. Fractionated CyberKnife Stereotactic Radiotherapy for Perioptic Pituitary Adenomas. World Neurosurg. 2019. PMID: 30902774. doi:10.1016/j.wneu.2019.03.102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。